Not medical advice. This website is not medical advice, a diagnosis, a match to a trial, or a recommendation to join a study. Listings are plain-English rewrites of public ClinicalTrials.gov records. Whether a site is still enrolling, and whether you qualify, can only be confirmed by the study team and your clinician. Source registry: ClinicalTrials.gov. Editorial rules: methodology.
RecruitingNot a traditional drug phaseobservationalRules rewrite
Not a traditional drug phase: Observational study, no intervention for Endometriosis
The goal of this watch-and-measure (no experimental treatment required) study is to determine the clinical validity of a deep neural network algorithm that utilizes protein biomarker detection of Endometriosis - "EndoCheck" - as an "aid in diagnosis" for endometriosis and to show validity as a diagnostic test
This is an observational study. You are not assigned a new experimental drug. Researchers measure what already happens in your care or in daily life.
Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.
What the registry says happens
This listing is observational (StudyType). The registry does not assign a new experimental drug as the study intervention.
They plan to enroll about 1,200 people at 10 sites. Taking part typically means study visits and measurements plus check-ins.
Official title (unrewritten)
Deep Neural Network Stratification for the Use in Detecting Endometriosis in Women Affected by Chronic Pelvic Pain (EndoCheck)
Interventions: Observational study, no intervention
Primary outcome (registry wording): Sensitivity and Specificity
Who it is for (from inclusion criteria)
Ages 14 Years to 50 Years
Women only
Participant is a female aged 14 to 50 years old at time of consent
Participant is scheduled to undergo laparotomy or laparoscopy for symptomology consistent with possible endometriosis
Who the registry excludes
Participant is a female in a pre-menarchal state
Participant is pregnant
Participant has an active malignancy
Participant is known to have tested positive for human immunodeficiency virus or hepatitis A, B, or C
Participant has an active pelvic infection or other infections contraindicated for surgery
Participant has participated (±3 months of study enrollment) in a clinical trial where an investigational drug/ device/ procedure was or is planned to be administered
Participant has any general health or behavioral condition that, in the opinion of the investigator, should exclude the participant from participation
This early phase I trial compares the side effects between patients treated with proton radiation therapy versus intensity modulated radiation therapy after surgery for the treatment of endometrial or cervical cancer. Radiation therapy uses high energy protons or x-rays to kill tumor cells and shrink tumors.
Endometriosis, a chronic gynecological disorder associated with pain and infertility, is a common condition affecting approximately one in ten women. Up to 50% of patients with endometriosis have ovarian endometriomas (or "chocolate cysts").
The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.
What phase is NCT05245695?
Not a traditional drug phase. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.
Can PlainTrials tell me if I qualify for NCT05245695?
No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.